Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.79 HKD | -2.86% | -8.86% | +1.65% |
15/04 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
15/04 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.65% | 603M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China